The Korea Disease Control and Prevention Agency said the national influenza vaccination program is proceeding normally, despite reports that some institutions have struggled to buy doses. The agency said those cases should not be interpreted as a disruption across the public health system. Production for the 2026-2027 season fell somewhat from the previous year after all vaccine strains recommended by the World Health Organization were changed and supplies of a type B reference material were delayed.

As of November 10, 19,057 of the 23,051 designated medical institutions, or 82.7%, still held remaining vaccine doses. The agency also reported that 72.9% of eligible older adults and 57.9% of eligible children receiving a first dose had been vaccinated. A total of 155,000 pregnant women had completed vaccination by that date. These figures describe different eligible groups and should not be combined into a single coverage rate.

The government said its routine procurement did not reduce the volume available to the private market. Working with manufacturers and importers, it supported the additional production of 1.05 million doses, with about 600,000 directed toward private-market supply. It also provided about 290,000 doses from government reserves to pediatric clinics that needed early stock after vaccination schedules were adjusted.

The agency said it will continue monitoring supply and operating the national vaccination program. The announcement confirms current vaccination activity and reported distribution measures, but it does not provide a forecast for when every private provider will have uninterrupted access to doses. People seeking vaccination should therefore check availability with a designated provider before visiting.